Asceneuron

Develops effective therapeutics for orphan tauopathies

Total raised

€27M

€27,000,000

Funding rounds

Investors

distinct backers

Active since

2015-08

latest 2015-08

Funding by year

EUR raised per year

High confidence

Raise-next likelihood18

base rate 44% for Series A

Timing: dormant vs cohort gap · momentum unknown. Funding-only estimates, not predictions and not investment advice — see signals.

1 rounds

Date	Stage	Amount	Investors
2015-09-01	Series A	€27M	Sofinnova Partners	View deal →

same sector or country